Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.
(2013) In Scandinavian Journal of Gastroenterology 48(3). p.259-265- Abstract
- Abstract Malignancies of the hepato-pancreatico-biliary (HPB) system are relatively common and generally characterized by a dismal prognosis. Positron emission tomography (PET) is a functional imaging technique that has emerged as an important modality in oncological decision-making. The principal radiopharmaceutical in PET imaging is the glucose analog (18)F-fluorodeoxyglucose, which is able to detect altered glucose metabolism in malignant tissue. PET is typically used in conjunction with computed tomography (CT), and previous studies have supported several uses of PET/CT in HPB malignancies, including staging, differential diagnostics and monitoring of treatment response and progress of disease. A review of PET/CT in the context of HPB... (More)
- Abstract Malignancies of the hepato-pancreatico-biliary (HPB) system are relatively common and generally characterized by a dismal prognosis. Positron emission tomography (PET) is a functional imaging technique that has emerged as an important modality in oncological decision-making. The principal radiopharmaceutical in PET imaging is the glucose analog (18)F-fluorodeoxyglucose, which is able to detect altered glucose metabolism in malignant tissue. PET is typically used in conjunction with computed tomography (CT), and previous studies have supported several uses of PET/CT in HPB malignancies, including staging, differential diagnostics and monitoring of treatment response and progress of disease. A review of PET/CT in the context of HPB malignancies will be presented, including indications and potential pitfalls. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3218990
- author
- Ansari, Daniel LU ; Keussen, Inger LU and Andersson, Roland LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Journal of Gastroenterology
- volume
- 48
- issue
- 3
- pages
- 259 - 265
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000315313400001
- pmid:23148675
- scopus:84875740508
- pmid:23148675
- ISSN
- 1502-7708
- DOI
- 10.3109/00365521.2012.704936
- language
- English
- LU publication?
- yes
- id
- 18765df4-82a5-4552-9df3-13a5a1f1563c (old id 3218990)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23148675?dopt=Abstract
- date added to LUP
- 2016-04-01 10:18:24
- date last changed
- 2022-04-04 08:44:23
@article{18765df4-82a5-4552-9df3-13a5a1f1563c,
abstract = {{Abstract Malignancies of the hepato-pancreatico-biliary (HPB) system are relatively common and generally characterized by a dismal prognosis. Positron emission tomography (PET) is a functional imaging technique that has emerged as an important modality in oncological decision-making. The principal radiopharmaceutical in PET imaging is the glucose analog (18)F-fluorodeoxyglucose, which is able to detect altered glucose metabolism in malignant tissue. PET is typically used in conjunction with computed tomography (CT), and previous studies have supported several uses of PET/CT in HPB malignancies, including staging, differential diagnostics and monitoring of treatment response and progress of disease. A review of PET/CT in the context of HPB malignancies will be presented, including indications and potential pitfalls.}},
author = {{Ansari, Daniel and Keussen, Inger and Andersson, Roland}},
issn = {{1502-7708}},
language = {{eng}},
number = {{3}},
pages = {{259--265}},
publisher = {{Taylor & Francis}},
series = {{Scandinavian Journal of Gastroenterology}},
title = {{Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.}},
url = {{http://dx.doi.org/10.3109/00365521.2012.704936}},
doi = {{10.3109/00365521.2012.704936}},
volume = {{48}},
year = {{2013}},
}